My CAR-T biopharmas, a brief observation.
When I sold out of ZioPharma, Cellectis, and Bluebird about a month ago and piled it all into Kite, I got a little flak about abandoning such promising companies, and how could I be so sure about one. I tried to explain that the others were promising for 2020 or 2021 or 2022, but that Kite is probably commercializing this November.
How are they doing? Here are weekly prices:
Kite
$103.10
$109.10
$111.40
$112.60
$120.05 - - - steadily moving up
Cellectis
$28.01
$26.83
$25.15
$23.25
$21.95 - - - rather shockingly moving down
Bluebird
$95.80
$96.05
$96.75
$95.00
$94.00 - - - going nowhere
ZioParma
$5.89
$6.10
$5.74
$5.82
$5.51 - - - going nowhere with a downward bias
Well Kite is up 16.4% in 4 weeks, the others are going nowhere or down, and all the others are below their price of four weeks ago. One month doesn’t give us a definitive answer, for sure, but for now it doesn’t look like it was a bad decision.
Saul